Document is current
Any future updates will be listed below
-
Authors
Fairley, Jessica L.
Hansen, Dylan
Ross, Laura
Proudman, Susanna
Sahhar, Joanne
Ngian, Gene-Siew
Walker, Jennifer
Host, Lauren V.
Morrisroe, Kathleen
Apostolopoulous, Diane
Ferdowsi, Nava
Wilson, Michelle
Tabesh, Maryam
Stevens, Wendy
Nikpour, Mandana
,
Cooley, Helen
Croyle, Lucy
Hill, Catherine
Host, Lauren
Lester, Sue
Major, Gabor
Nash, Peter
Rischmueller, Maureen
Roddy, Janet
Strickland, Gemma
Tay, Tien
Tymms, Kathleen
Youssef, Peter
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (GNT2013842, Investigator Grant GTN1197169, Investigator Grant GNT1176538)
Australian Government, Australia (Research Training Program Scholarship)
Arthritis Foundation of Australia (ARA Victoria Fellowship)
- License Information
-
More Information
Article History
Received: 13 February 2023
Accepted: 29 April 2023
First Online: 12 May 2023
Declarations
:
: The Australian Scleroderma Cohort Study has been approved by all Human Research Ethics Committees of participating sites. Written informed consent was obtained from all participants prior to the collection of any study data. This study is conducted in accordance with the Declaration of Helsinki.
: Not applicable; aggregate data only presented.
: The Australian Scleroderma Interest Group received research support grants from Actelion. SP has received honoraria from Janssen. JS and JW have received honoraria from Boehringer Ingelheim Pty Ltd. WS has received consultancies from Jansenn and Boehringer-Ingelheim. MN has received honoraria or consultancies from Janssen, AstraZeneca, GlaxoSmithKlein, Boehringer-Ingelheim and Bristol-Myers Squibb. JF has received conference sponsorship from Pfizer and honoraria from Boehringer-Ingelheim. LH has been a paid speaker for the Limbic publication.
